Farallon Capital acquires 460-unit multifamily community La Vista apartments in Santa Maria California. Farallon Capital has picked up La Vista, a 460-unit community in Santa Maria, California. Los Angeles-based Westview Capital sold the asset. Located at 740 S. Western Ave., the 26-building property opened in 1978. It sits on more than 31 acres in an Opportunity Zone. Multiple dining and retail options are within walking distance, with downtown Santa Maria less than 2 miles northeast. The community comprises studios and one- to three-bedroom floorplans ranging from 393 to 1,300 square feet. All units have washer-dryers, microwaves and kitchens with breakfast bars. Select apartments also include kitchen pantries and private balconies or patios. The pet-friendly La Vista features a community room, a playground, a barbecue area, two swimming pools, two spas and more than 700 parking spaces. La Vista is not Farallon Capital's sole multifamily asset in a tertiary California market. Together with Ridge Capital Investors, the company acquired the 107-unit Wimbledon Square in Lodi, in Central Valley. The property traded for $16.2 million just last month.

New funding from US and European-based investors, including Farallon Capital, Red River West and Bertelsmann Investments, follows a $90 million raise in May 2021. Schroders Capital acquires secondary shares through public and private vehicles. Funding will be used to accelerate Ada Health’s rapid growth and strengthen company’s presence in the United States following strong traction in the region.

Funding rounds for AI training, fintech AI, robotics services and biotech firms. Recent Series A and later-stage financings across AI, robotics and biotech illustrate capital allocation to specialised training environments, fintech decisioning, outcome-based automation and RNA-based therapeutics. Artificial intelligence. Synapse Analytics, an Abu Dhabi-based AI company that provides agentic decision-making infrastructure for regulated lenders, raised $13 million in a Series A led by Paris-based Partech, with participation from Cairo's Algebra Ventures and Silicon Badia. The funding lifts total capital to $17 million and will be used to enlarge the engineering team, accelerate product development for credit-risk decisioning, and expand the firm's presence across the Middle East, Africa and Latin America, where it reports a more than five-fold revenue increase since its 2025 relaunch. [6] Anew Labs, the AI-driven drug-discovery unit spun out of ByteDance, completed a Series A valued at $290 million according to Dealroom, with the round led by HSG, IDG Capital and Hillhouse Investment and co-lead by 5Y Capital, alongside participation from Gaorong Ventures, Primavera Venture Partners and several state-backed funds. The financing will support development of its structure-prediction and protein-design models, Protenix and PXDesign, and advance four drug candidates, while ByteDance retains a 56 percent stake. [5] Robotics. Extend Robotics, a UK-based embodied-AI firm that sells completed factory work rather than robots, closed a £2.6 million early-stage round led by Skyworks Venture Capital Fund, with participation from Neo Venture (Europe) and Zip Capital. The money will be used to scale its Result-as-a-Service offering across the UK and Europe, expand its remote-operator network and grow the AMAS platform that lets non-robotics specialists control robot arms or humanoids via an immersive 3D interface, with AI handling routine task portions. [1] Tangent Robotics, a New York spin-out of Columbia University's Robotic Manipulation and Mobility Lab, raised $4.5 million in pre-seed funding led by Fly Ventures and Toyota Ventures. The capital will support development of its fine-motor-skill layer that combines light-based touch sensors, human-motion-tracked robotic hands and machine-learning-driven motor learning, targeting high-precision assembly, threading and connector-mating tasks in manufacturing. Co-founders Pedro Piacenza and Matei Ciocarlie highlighted the aim to reduce robot skill acquisition time from days to hours. [2] RobotPlusPlus (ROBOT++) completed a Series C described as "hundreds of millions of RMB (tens of millions of USD)" led by Qianggang Capital Fund, with participation from GIG Capital Group, Sealand Innovation, Juntong Capital and an increased stake by Fosun RZ Capital. The round will fund global expansion of its special-purpose industrial robots, including hull-derusting fleets deployed in over 100 shipyards, and further embodied-AI development for hazardous tasks across shipyards, oil-and-gas sites, wind farms and building façades, leveraging its R&D-heavy model that has amassed over 2 million operating hours. [3] Genetic engineering. Innovate UK announced the Engineering Biology Investor Partnerships Round 1, offering up to £8 million in grant funding to UK-registered SMEs developing engineering-biology products and services, with the requirement that applicants secure aligned investment from a lead investor in the programme's pool. Grants range from £250 000 to £2 million for projects of 24-month duration, aiming to support late-stage experimental development and commercialisation of engineering-biology technologies, with additional commercial expertise provided by participating investors. [4] Encoded Therapeutics, a South San Francisco company that creates one-time precision genetic medicines for severe neurological disorders, raised $275 million in a Series F co-led by GV and a healthcare fund, with participation from ARCH Venture Partners, Braidwell, Farallon Capital Management, Illumina Ventures, Invus, Janus Henderson, Matrix Capital, Nolan Capital, RTW Investments, SoftBank Vision Fund 2 and Venrock. Proceeds will fund a pivotal study of ETX101 in infants and children with SCN1A-positive Dravet syndrome, an expansion study up to age 18, scale-up of GMP manufacturing and advancement of ETX301 toward a 2027 IND submission for post-amputation neuroma pain. [5]